## Village Health A product of SCAN Health Plan®

## **Avastin**

Express Scripts
Prior Authorization
Phone 1-844-424-8886
Fax 1-877-251-5896

To start your Part D Coverage Determination request, you (or your representative or your doctor or other prescriber) should contact Express Scripts, Inc (ESI):

- You may Call ESI at 1-844-424-8886, 24 hours a day, 7 days a week, TTY users: 1-800-716-3231
- You may Fax your request to: 1-877-251-5896 (Attention: Medicare Reviews)
- You may also send your request via email to: <a href="mailto:medicarepartdparequests@express-scripts.com">medicarepartdparequests@express-scripts.com</a>

Member's Last Name:	Member's First Name:
SCAN ID number:	Date of Birth:
Prescriber's Name:	Contact Person:
Office phone:	Office Fax:
Medication:	Diagnosis:

This drug may be covered under Medicare Part B or Part D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

SECTION A		Α	<u>Please answer the following questions</u>	
	1.	θYes	θ Νο	Is the diagnosis or indication for the treatment of patients with Metastatic
				Colorectal Cancer? (If No, skip to question 5.)
	2.	$\theta$ Yes	θ Νο	Has the patient's metastatic colorectal cancer progressed after receiving a
				first-line Avastin-containing regimen? (If Yes, skip to question 4)
	3.	$\theta$ Yes	θ Νο	Will Avastin be used in combination with intravenous 5-fluorouracil - based
				chemotherapy? NOTE: Also answer YES if the member has used a drug
				with the same active ingredient as the generic intravenous 5-fluorouracil (e.g.,
				Adrucil).
	4.	$\theta$ Yes	θ Νο	Will Avastin be used in combination with fluoropyrimidine-irinotecan- or
				fluoropyrimidine-oxaliplatin-based chemotherapy? (Skip to question 18.)
	5.	$\theta$ Yes	θ Νο	Is the diagnosis or indication for the adjuvant treatment of colon cancer?
	6.	$\theta$ Yes	θ Νο	Is the diagnosis or indication for the treatment of patients with Non-Squamous
				Non-Small Cell Lung Cancer? (If No, skip to question 9.)
	7.	θYes	θ Νο	Will Avastin be used in patients whose disease is unresectable, locally
		0.00	J . 10	advanced, recurrent or metastatic?

8.	$\theta$ Yes	θ Νο	Will Avastin be used in combination with carboplatin and paclitaxel? (Skip to question 18.)
9.	$\theta$ Yes	θ Νο	Is the diagnosis or indication for the treatment of patients with Metastatic
10	0 Vaa	0 Na	Renal Cell Carcinoma? (If No, skip to question 11.)
10.	θ Yes	θ Νο	Will Avastin be used in combination with interferon alfa? (Skip to question 18.)
11.	θ Yes	θ Νο	Is the diagnosis or indication for the treatment of patients with recurrent
40			Glioblastoma? (If Yes, skip to question 18.)
12.	θ Yes	θ Νο	Is the diagnosis or indication for the treatment of patients with Metastatic
4.0			Breast Cancer? (If Yes, skip to question 18.)
13.	θ Yes	θ Νο	Will Avastin be used in patients with persistent, recurrent, or metastatic
			cervical cancer? (If No, skip to question 15.)
14.	θ Yes	θ Νο	Will Avastin be used in combination with paclitaxel and cisplatin or paclitaxel
			and topotecan? (Skip to question 18.)
15.	θ Yes	θ Νο	Will Avastin be used in patients with platinum-resistant or platinum-sensitive
			recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer?
			θ Platinum-resistant (Skip to question 16)
			$\theta$ Platinum-sensitive (Skip to question 17)
16.	$\theta$ Yes	$\theta$ No	Will Avastin be used in combination with paclitaxel, pegylated liposomal
			doxorubicin or topotecan?
	If <b>NO</b> ,	please	document the diagnosis:
17.	θYes	θ Νο	Will Avastin be used in combination with carboplatin and paclitaxel, or in
	0.00	0.10	combination with carboplatin and gemcitabine, followed by Avastin as a single
			agent?
18.	θYes	θ Νο	Is the prescription written or recommended by an Oncologist?
19.	θ Yes	θ Νο	Will Avastin be administered in patients with any of the following:
	0 103	0 110	gastrointestinal perforation; wound dehiscence requiring medical intervention;
			OR serious hemorrhage or recent history of hemoptysis of one and a half or
			greater teaspoon of red blood?
20.	θYes	θ Νο	Will Avastin be administered in patients who experienced a severe arterial
_0.	0 103	0 110	thromboembolic event including cerebral infarction, transient ischemic attacks,
			or myocardial infarction?
21.	θYes	θ Νο	Does member have any of the following:
	0 103	0 110	tracheoesophageal (TE) fistula, fistula formation involving an internal
			organ, or any Grade 4 fistula?
22.	θ Yes	θ Νο	Is the member currently taking the requested medication?
23.	θ Yes		
20.	0 163	UNU	other pharmacies?
24.	θYes	θ Νο	·
۷٦.			document how the medication is supplied:
	11 <b>140</b> ,	picase	иосители пом иле тесновноги в заррнеи.
Pla	ase de	Cumen	t the symptoms and/or any other information important to this review:
, ,	ase uc	Cumen	t the symptoms and/or any other information important to this review.

SECTION B Physician Signature

PHYSICIAN SIGNATURE	DATE

## **FAX COMPLETED FORM TO: 1-877-251-5896**

Our response time for prescription drug coverage standard requests is 72 hours. If you or your prescriber believe that waiting 72 hours for a standard decision could seriously harm your life, health, or ability to regain maximum function, you can ask for an expedited (fast) decision. If your prescriber indicates that waiting 72 hours could seriously harm your health, we will automatically give you a decision within 24 hours. If you do not obtain your prescriber's support for an expedited request, we will decide if your case requires a fast decision. You cannot request an expedited coverage determination if you are asking us to pay you back for a drug you already received. View our formulary and Prior Authorization criteria online at <a href="http://www.villagehealthca.com">http://www.villagehealthca.com</a>